Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Performer
6392.5000 48.50 (0.76%)
NSE Jan 02, 2026 15:31 PM
Volume: 108.5K
 

6392.50
0.76%
Phillip Capital
Top takeaways from Q1FY17: Delivered strong Q1 operating performance with 17% beat in earnings supported by 310bps positive surprise in margins and 6% beat in revenues. Guides for delayed commercialisation of its new projects –at Kakinada SEZ as well as at Vizag – during late FY18. This could hurt the modelled sales growth of 19% in FY18. Divi’s board has approved a one?time ex?gratia of Rs 790mn for its employees on the occasion of its 25th anniversary and that would hurt FY17 margins by ~150bps. Phillip Capital maintain their Neutral rating with raised TP of Rs 1200 (vs. Rs 1190 earlier).
Divi's Laboratories Ltd. is trading below its 30 day SMA of 6408.6
More from Divi's Laboratories Ltd.
Recommended